Cryoprevention of Chemotherapy-Induced Oral Mucositis

Loading...
Thumbnail Image

Journal Title

Journal ISSN

Volume Title

Publisher

Abstract

Oral mucositis (OM) is described as one of the most severe side effects of cancer therapy, causing immense pain that may significantly compromise treatment outcomes and increase healthcare costs. Cryoprevention using ice (IC) is a well-substantiated and recommended strategy for the prevention of chemotherapy-induced OM. However, the use of IC is associated with adverse reactions and infection risks from contaminated water. Evidence is also limited regarding optimal cooling temperature, timing and duration, leaving room for further optimization and increased tolerability of this modality. Furthermore, accurate diagnosis is essential for effective management of this condition. The rationale for this thesis was to provide new insights into cryoprevention for chemotherapy-induced OM to improve the supportive care of cancer patients. The specific aims were to: (i) compare the intraoral cooling device (ICD) and IC in the prevention of OM (defined as peak OMAS-total) in a randomized controlled trial involving myeloma and lymphoma patients receiving high-dose chemotherapy in conjunction with hematopoietic stem cell transplantation; (ii) evaluate intraoral temperature reduction and tolerability using the ICD set to 8 °C and 15 °C, respectively, during 30 and 60 minutes of cooling; (iii) examine the trajectory of the intraoral temperature reduction using IC and ICD set to 8 °C and 15 °C, respectively, during a 30-minute cooling period; and (iv) evaluate interrater reliability between nurses and dentists specialized in orofacial medicine regarding OM assessments. The ICD was equally effective as IC in preventing OM in myeloma patients, and even more effective in the lymphoma group (Study I). The ICD set to 15 °C was inferior to 8 °C in terms of reducing intraoral temperature (Study II). The greatest drop in intraoral temperature was seen after 5 minutes of cooling with IC, the ICD set to 15 °C and 8 °C, respectively (Study III). For OM of any grade, the overall interrater reliability between nurses and dentists specialized in orofacial medicine was found to be fair (Study IV). This thesis highlights that the ICD is promising in the prevention of OM and that cooling does not necessarily have to be prolonged or extremely cold to achieve clinical effect. This enables more individualized and tolerable cooling protocols. At the same time, the results highlight the need for increased knowledge, training and interprofessional collaboration in the diagnosis and management of OM.

Description

Keywords

Cryotherapy, Intraoral cooling device, Oral mucositis, Multiple myeloma, Lymphoma, Hematopoietic stem cell transplantation, High-dose chemotherapy, Tolerability, Randomized controlled trial

Citation

ISBN

978-91-8115-639-3 (Tryckt)
978-91-8115-640-9 (PDF)

Articles

I. Walladbegi J., Henriksson R., Tavelin B., Svanberg A., Larfors G., Jadersten M., Schjesvold F., Mahdi A., Garmin Legert K., Peterson E. D., Jontell M. Efficacy of a novel device for cryoprevention of oral mucositis: a randomized, blinded, multicenter, parallel group, phase 3 trial. Bone Marrow Transplantation 2022;57:191–7. http://doi.org/10.1038/s41409-021-01512-6

II. Mahdi A., Stubner J., Bergling M., Jontell M., Walladbegi J. Can cryoprevention of oral mucositis be obtained at a higher temperature? Clinical Oral Investigations 2021;25:4519–26. http://doi.org/10.1007/s00784-020-03765-9

III. Ibrahim A., Camci E., Khairallah L., Jontell M., Walladbegi J. Cryopreventive temperatures prior to chemotherapy. Medical Oncology 2023;40:1–7. http://doi.org/10.1007/s12032-023-01989-9

IV. Ibrahim A., Mahmoud D., Mavandadipur H., Walladbegi J. Interrater Reliability in the Assessment of Oral Mucositis among Patients Receiving High-Dose Chemotherapy: A Multicenter Comparison between Specialized Dentists and Registered Nurses. BMC Cancer 2025;25:1874–7. http://doi.org/10.1186/s12885-025-14670-3

Department

Institute of Odontology. Department of Oral and Maxillofacial Surgery

Defence location

Fredagen den 6 mars 2026, kl. 9.00, Europasalen, Konferenscentrum Wallenberg, Medicinaregatan 20, Göteborg

Endorsement

Review

Supplemented By

Referenced By